MYOK - MyoKardia, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
42.85
-1.54 (-3.48%)
As of 2:41PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close44.39
Open44.67
Bid42.930 x 800
Ask43.130 x 1100
Day's Range42.62 - 45.31
52 Week Range39.16 - 67.79
Volume199,074
Avg. Volume284,469
Market Cap1.725B
Beta (3Y Monthly)3.43
PE Ratio (TTM)N/A
EPS (TTM)-1.372
Earnings DateMar 6, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est75.00
Trade prices are not sourced from all markets
  • GlobeNewswire6 hours ago

    MyoKardia Appoints William Fairey as Chief Commercial Officer

    MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of William C. Fairey as Chief Commercial Officer and Executive Vice President.  Mr. Fairey will have global responsibility for oversight of all aspects of commercial operations and serve as a key member of MyoKardia’s executive leadership team. “Bill is a leader with a strong and relevant track record in building mission-driven, high-performing teams that have brought important therapies to patients with few if any options,” said Tassos Gianakakos, Chief Executive Officer of MyoKardia.

  • GuruFocus.com10 days ago

    Weekly CEO Buys Highlight

    Details the CEO buys this past week for the following companies: Medtronic PLC, OPKO Health, Hartford Financial Services and MyoKardia

  • TheStreet.com14 days ago

    Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019

    just went public on Dec 7, to an immediate "Strong Buy" rating from eight market analysts. In an impressive open, and the biotech sector's largest IPO, the company raised over $600 million to reach a total value of about $7.4 billion. The company takes a novel approach to the creation of new drugs, basing its research on mRNA, the genetic material that transfers instructions from DNA into completed proteins.

  • GlobeNewswire20 days ago

    MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of.

  • Why Tesla, MyoKardia, and Hologic Slumped Today
    Motley Fool21 days ago

    Why Tesla, MyoKardia, and Hologic Slumped Today

    Learn about 2019's first-day losers in the stock market.

  • GlobeNewswire21 days ago

    MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi

    MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced it has regained worldwide rights to all programs covered under its license and collaboration agreement with Sanofi. The collaboration will not be extended beyond the initial research term, which ended on December 31, 2018, and will conclude in its entirety effective April 1, 2019. As a result, MyoKardia now has global rights to all programs in its portfolio, including lead clinical-stage candidates, mavacamten and MYK-491.

  • Hedge Funds Are Buying MyoKardia, Inc. (MYOK)
    Insider Monkeylast month

    Hedge Funds Are Buying MyoKardia, Inc. (MYOK)

    Is MyoKardia, Inc. (NASDAQ:MYOK) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]

  • Is MyoKardia Inc (NASDAQ:MYOK) As Strong As Its Balance Sheet Indicates?
    Simply Wall St.2 months ago

    Is MyoKardia Inc (NASDAQ:MYOK) As Strong As Its Balance Sheet Indicates?

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as MyoKardia Inc (NASDAQ:MYOK), with a market capitalization of US$2.5b, rarely draw their attention from the investing community. Read More...

  • GlobeNewswire2 months ago

    MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions

    MyoKardia is developing mavacamten for the chronic treatment of hypertrophic cardiomyopathy (HCM), a heritable disease caused by the presence of too many cross-bridges formed between the heart muscle proteins myosin and actin. Mavacamten is intended to normalize this excess cross-bridge formation, which underlies the hypercontractility, or elevated force of contraction, and the reduced compliance, or ability of the left ventricle to relax and fill with oxygenated blood, that are both characteristic of HCM.

  • Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion — for a higher price
    American City Business Journals2 months ago

    Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion — for a higher price

    One of the first tenants in The Cove at Oyster Point is taking the last building in the South San Francisco development as rents in the region hit new highs.

  • MyoKardia (MYOK) Reports Q3 Loss, Tops Revenue Estimates
    Zacks3 months ago

    MyoKardia (MYOK) Reports Q3 Loss, Tops Revenue Estimates

    MyoKardia (MYOK) delivered earnings and revenue surprises of 22.00% and 21.45%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    MyoKardia: 3Q Earnings Snapshot

    The South San Francisco, California-based company said it had a loss of 39 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • All this 500,000-square-foot Berkeley biotech project needs is a developer
    American City Business Journals3 months ago

    All this 500,000-square-foot Berkeley biotech project needs is a developer

    An eight-acre Berkeley site near Aquatic Park has hit the market, promoted as a potential 475,000-square-foot office project or life science campus. Commercial brokerage firm JLL (NYSE: JLL) is marketing the site at the foot of Addison Street, east of Interstate 80, to potential developers that could take advantage of a biotech building boom in which hundreds of thousands of square feet are being taken quickly, often months before structures are completed.

  • GlobeNewswire3 months ago

    MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of.

  • GlobeNewswire3 months ago

    MyoKardia Announces Twelve Abstracts Accepted for Presentation During the 2018 American Heart Association Scientific Sessions

    Presentations Include Data from Ongoing Clinical Trials and Preclinical Studies of Mavacamten and HCM Population Insights from the Sarcomeric Human Cardiomyopathy Registry.

  • GlobeNewswire3 months ago

    MyoKardia to Present Clinical Evidence of Mavacamten’s Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions

    Diastolic Relaxation Typically Impaired in HCM Patients; Data Indicate Mavacamten May Improve Ability of the Left Ventricle to Relax and Fill Additional Clinical Evidence of.

  • Big pharma leases almost 500,000 square feet for new research center
    American City Business Journals3 months ago

    Big pharma leases almost 500,000 square feet for new research center

    It is one of the largest real estate leases in the Bay Area by traditional drug companies staking out space to establish deeper research and development connections with the region’s hundreds of biotech companies and research universities.

  • TheStreet.com3 months ago

    Bears Are Doing an EKG Test on MyoKardia

    MYOK is a company that is involved with treating cardiovascular disease. Gianakakos said even though one-third of all people die from some form of cardiovascular disease, there's been little innovation in the space. To get to the cause, you need precision medicine, Gianakakos said, and that's what MyoKardia is doing.

  • GlobeNewswire3 months ago

    MyoKardia Shares Data from Ongoing Clinical Programs and Details Three New Research Programs at 2018 R&D Day

    Interim PIONEER-OLE Data for Mavacamten Demonstrate Reductions in LVOT Obstruction; Ejection Fraction Maintained above Normal Range First-in-Human Data for MYK-491 in Healthy.

  • Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more
    American City Business Journals3 months ago

    Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more

    Small VistaGen is building a portfolio of drugs aimed at depression and other mental health conditions, while giant Gilead gets a lower effective tax rate — all that and more in our Health Care Digest.

  • MyoKardia (MYOK) Q3 Earnings Preview: What's Shaping Up?
    Zacks3 months ago

    MyoKardia (MYOK) Q3 Earnings Preview: What's Shaping Up?

    MyoKardia (MYOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.